The NIAID radiation countermeasures program business model

Biosecurity and Bioterrorism

Volumn 8, Issue 4, 2010, Pages 357-363

  Hafer, Nathaniel ^a   Maidment, Bert W ^b   Hatchett, Richard J ^b  

^a AAAS   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; FINANCIAL MANAGEMENT; HUMAN; NATIONAL HEALTH ORGANIZATION; NONBIOLOGICAL MODEL; NUCLEAR ACCIDENT; ORGANIZATION AND MANAGEMENT; PUBLIC-PRIVATE PARTNERSHIP; RADIATION INJURY; REVIEW; UNITED STATES;

DRUG DISCOVERY; HUMANS; MODELS, ORGANIZATIONAL; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); PUBLIC-PRIVATE SECTOR PARTNERSHIPS; RADIATION INJURIES; RADIOACTIVE HAZARD RELEASE; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 78650267246     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2010.0041     Document Type: Review

References (16)

1. FDA Final Rule. http://www.fda.gov/OHRMS/DOCKETS/98fr/053102a.htm. Accessed July 29, 2010.
2. FDA Guidance for Industry, Animal Models-Essential Elements to Address Efficacy Under the Animal Rule. http://www.fda.gov/downloads/Drugs/ GuidanceCompliance RegulatoryInformation/Guidances/UCM078923.pdf. Accessed July 29, 2010.
3. National Biodefense Science Board Report. Where Are the Countermeasures? Protecting America's Health from CBRN Events. http://www.phe.gov/Preparedness/ planning/nbsb/meetings/Documents/nbsb-mcmreport.pdf. Accessed August 3, 2010.
4. NIAID Radiation/Nuclear Medical Countermeasures homepage. http://www.niaid.nih.gov/topics/radnuc/Pages/default.aspx. Accessed July 29, 2010.
5. Information about NIAID's CMCR program can be found here: http://www.niaid.nih.gov/topics/radnuc/funding/pages/cmcr.aspx. Accessed September 24, 2010.
6. Maidment B, Benjamin J, Cassatt D, et al. Radiation/Nuclear Medical Countermeasures Development Program. Proceedings of the 12th International Congress of the International Radiation Protection Association [online]; 2008. http://www.irpa12.org.ar/fullpapers/FP0831.pdf. Accessed July 29, 2010.
7. Hafer N, Cassatt D, DiCarlo A, et al. NIAID/NIH Radiation/Nuclear Medical Countermeasures Product Research and Development Program. Health Physics Journal 2010;98:903-905.
8. SBIR website. http://grants.nih.gov/grants/guide/pa-files/pa-09-093.html. Accessed July 29, 2010.
9. RAID website. http://nihroadmap. nih.gov/raid/. Accessed July 29, 2010.
10. NCI Radiation Research Program website. http://www3. cancer.gov/rrp/ index.shtml. Accessed July 29, 2010.
11. Williams JP, Brown SL, Georges GE, et al. Animal models for medical countermeasures to radiation exposure. Radiat Res 2010 Apr; 173(4):557-578.
12. Public Workshop: Animal Models for the Treatment of Acute Radiation Syndrome. http://www.fda.gov/BiologicsBlood Vaccines/NewsEvents/ WorkshopsMeetingsConferences/ucm 163937.htm. Accessed September 24, 2010.
13. NCI NIAID meeting website. http://www3.cancer.gov/rrp/ini-workshop.shtml. Accessed July 29, 2010.
14. Mosvas B, Vikram B, Hauer-Jensen M, et al. Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators (submitted). Advanced Radiation Therapeutics-Radiation Injury Mitigation. http://www3.cancer.gov/rrp/workshop- 2010/rrp-workshop.pdf. Accessed July 29, 2010.
15. More information about this NCI-sponsored SBIR program is available here: http://grants.nih.gov/grants/funding/SBIRContract/PHS2011-1.pdf. Accessed September 28, 2010.
16. Farese AM, Cohen MV, Gibbs AM, et al. Filgrastim administration significantly improves survival in nonhuman primates following a 50% lethal dose of total body irradiation. Radiation Research Society Annual Meeting; Savannah, GA; Poster Session 5.40; October 2009.